

Audit Review Table

Coventry Health & Life Insurance Company dba CoventryCares of Kentucky (Org ID: 19497, SubID: 10962, Medicaid, Spec Area: None, Spec Proj: None); Measurement Year - 2013

This submission is unlocked.

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
Effectiveness of Care: Prevention and Screening						
Adult BMI Assessment (aba)	Y			60.88%	R	
Weight Assessment and Counseling for Nutrition and Physical Activity for	Y					
<i>BMI Percentile</i>				25.00%	R	
<i>Counseling for Nutrition</i>				23.84%	R	
<i>Counseling for Physical Activity</i>				21.99%	R	
Childhood Immunization Status (cis)	Y					
<i>DTaP</i>				78.19%	R	
<i>IPV</i>				91.18%	R	
<i>MMR</i>				90.26%	R	
<i>HiB</i>				93.04%	R	
<i>Hepatitis B</i>				87.70%	R	
<i>VZV</i>				92.11%	R	
<i>Pneumococcal Conjugate</i>				79.12%	R	
<i>Hepatitis A</i>				72.39%	R	
<i>Rotavirus</i>				60.79%	R	
<i>Influenza</i>				35.50%	R	
<i>Combination #2</i>				71.69%	R	
<i>Combination #3</i>				67.52%	R	
<i>Combination #4</i>				54.52%	R	
<i>Combination #5</i>				48.96%	R	
<i>Combination #6</i>				26.91%	R	
<i>Combination #7</i>				42.23%	R	
<i>Combination #8</i>				23.90%	R	
<i>Combination #9</i>				22.04%	R	
<i>Combination #10</i>				20.19%	R	
Immunizations for Adolescents (ima)	Y					
<i>Meningococcal</i>				76.62%	R	
<i>Tdap/Td</i>				86.11%	R	
<i>Combination #1</i>				75.23%	R	
Human Papillomavirus Vaccine for Female Adolescents (hvp)	Y			16.32%	R	
Lead Screening in Children (lsc)	Y			66.13%	R	
Breast Cancer Screening (bcs)	Y			NA	R	
Cervical Cancer Screening (ccs)	Y			51.41%	R	
Non-Recommended Cervical Cancer Screening in Adolescent Females (ncs)	Y			9.62%	R	
Chlamydia Screening in Women (chl)	Y					
<i>16-20 Years</i>				44.13%	R	
<i>21-24 Years</i>				58.71%	R	
<i>Total</i>				48.27%	R	
Effectiveness of Care: Respiratory Conditions						
Appropriate Testing for Children with Pharyngitis (cwp)	Y	Y		62.72%	R	
Appropriate Treatment for Children With URI (uri)	Y	Y		58.33%	R	
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (aab)	Y	Y		16.60%	R	
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (spr)	Y			NA	R	
Pharmacotherapy Management of COPD Exacerbation (pce)	Y	Y				
<i>Systemic Corticosteroid</i>				65.10%	R	
<i>Bronchodilator</i>				80.66%	R	
Use of Appropriate Medications for People With Asthma (asm)	Y	Y				
<i>5-11 Years</i>				94.38%	R	
<i>12-18 Years</i>				88.38%	R	
<i>19-50 Years</i>				57.89%	R	

51-64 Years				50.00%	R	
Total				84.31%	R	
Medication Management for People With Asthma (mma)	Y	Y				
5-11 Years - Medication Compliance 50%				67.98%	R	
5-11 Years - Medication Compliance 75%				42.92%	R	
12-18 Years - Medication Compliance 50%				65.91%	R	
12-18 Years - Medication Compliance 75%				43.28%	R	
19-50 Years - Medication Compliance 50%				66.77%	R	
19-50 Years - Medication Compliance 75%				46.11%	R	
51-64 Years - Medication Compliance 50%				86.17%	R	
51-64 Years - Medication Compliance 75%				63.83%	R	
Total - Medication Compliance 50%				67.72%	R	
Total - Medication Compliance 75%				44.04%	R	
Asthma Medication Ratio (amr)	Y	Y				
5-11 Years				85.71%	R	
12-18 Years				71.74%	R	
19-50 Years				38.81%	R	
51-64 Years				38.83%	R	
Total				71.31%	R	
Effectiveness of Care: Cardiovascular						
Cholesterol Management for Patients With Cardiovascular Conditions (cmc)	Y					
LDL-C Screening Performed				79.63%	R	
LDL-C Control (<100 mg/dL)				29.63%	R	
Controlling High Blood Pressure (cbp)	Y		N	54.22%	R	
Persistence of Beta-Blocker Treatment After a Heart Attack (pbh)	Y	Y		89.87%	R	
Effectiveness of Care: Diabetes						
Comprehensive Diabetes Care (cdc)	Y					
Hemoglobin A1c (HbA1c) Testing				83.08%	R	
HbA1c Poor Control (>9.0%)				45.73%	R	
HbA1c Control (<8.0%)				45.43%	R	
HbA1c Control (<7.0%)				36.38%	R	
Eye Exam (Retinal) Performed				38.11%	R	
LDL-C Screening Performed				78.66%	R	
LDL-C Control (<100 mg/dL)				28.81%	R	
Medical Attention for Nephropathy				79.57%	R	
Blood Pressure Control (<140/80 mm Hg)				32.16%	R	
Blood Pressure Control (<140/90 mm Hg)				52.13%	R	
Effectiveness of Care: Musculoskeletal						
Disease Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis (art)	Y	Y		65.84%	R	
Use of Imaging Studies for Low Back Pain (lbp)	Y			69.18%	R	
Effectiveness of Care: Behavioral Health						
Antidepressant Medication Management (amm)	Y	Y				
Effective Acute Phase Treatment				59.33%	R	
Effective Continuation Phase Treatment				42.59%	R	
Follow-Up Care for Children Prescribed ADHD Medication (add)	Y	Y				
Initiation Phase				49.85%	R	
Continuation and Maintenance (C&M) Phase				52.68%	R	
Follow-Up After Hospitalization for Mental Illness (fuh)	Y	Y				
30-Day Follow-Up				63.37%	R	
7-Day Follow-Up				38.98%	R	
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (ssd)	Y	Y		75.32%	R	
Diabetes Monitoring for People With Diabetes and Schizophrenia (smd)	Y			71.21%	R	

Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (smc)	Y			NA	R	
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (saa)	Y	Y		61.79%	R	
Effectiveness of Care: Medication Management						
Annual Monitoring for Patients on Persistent Medications (mpm)	Y	Y				
<i>ACE Inhibitors or ARBs</i>				88.97%	R	
<i>Digoxin</i>				90.24%	R	
<i>Diuretics</i>				89.80%	R	
<i>Anticonvulsants</i>				64.23%	R	
<i>Total</i>				87.07%	R	
Access/Availability of Care						
Adults' Access to Preventive/Ambulatory Health Services (aap)	Y					
<i>20-44 Years</i>				86.43%	R	
<i>45-64 Years</i>				92.16%	R	
<i>65+ Years</i>				86.47%	R	
<i>Total</i>				88.62%	R	
Children and Adolescents' Access to Primary Care Practitioners (cap)	Y					
<i>12-24 Months</i>				95.46%	R	
<i>25 Months - 6 Years</i>				92.42%	R	
<i>7-11 Years</i>				97.57%	R	
<i>12-19 Years</i>				96.39%	R	
Annual Dental Visit (adv)	Y	Y				
<i>2-3 Years</i>				37.77%	R	
<i>4-6 Years</i>				68.16%	R	
<i>7-10 Years</i>				67.10%	R	
<i>11-14 Years</i>				61.13%	R	
<i>15-18 Years</i>				53.24%	R	
<i>19-21 Years</i>				38.62%	R	
<i>Total</i>				59.22%	R	
Initiation and Engagement of AOD Dependence Treatment (iet)	Y	Y				
<i>Initiation of AOD Treatment: 13-17 Years</i>				31.66%	R	
<i>Engagement of AOD Treatment: 13-17 Years</i>				9.17%	R	
<i>Initiation of AOD Treatment: 18+ Years</i>				31.47%	R	
<i>Engagement of AOD Treatment: 18+ Years</i>				5.27%	R	
<i>Initiation of AOD Treatment: Total</i>				31.48%	R	
<i>Engagement of AOD Treatment: Total</i>				5.63%	R	
Prenatal and Postpartum Care (ppc)	Y		N			
<i>Timeliness of Prenatal Care</i>				82.41%	R	
<i>Postpartum Care</i>				50.93%	R	
Call Answer Timeliness (cat)	Y			85.31%	R	
Utilization						
Frequency of Ongoing Prenatal Care (fpc)	Y		N			
<i><21 Percent</i>				10.56%	R	
<i>21-40 Percent</i>				5.59%	R	
<i>41-60 Percent</i>				9.72%	R	
<i>61-80 Percent</i>				20.40%	R	
<i>81+ Percent</i>				53.73%	R	
Well-Child Visits in the First 15 Months of Life (w15)	Y					
<i>0 Visits</i>				2.78%	R	
<i>1 Visit</i>				2.78%	R	
<i>2 Visits</i>				3.71%	R	
<i>3 Visits</i>				6.73%	R	
<i>4 Visits</i>				10.44%	R	
<i>5 Visits</i>				15.78%	R	
<i>6+ Visits</i>				57.77%	R	
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (w34)	Y			62.73%	R	
Adolescent Well-Care Visits (awc)	Y			46.30%	R	
Frequency of Selected Procedures (fsp)	Y				R	
Ambulatory Care: Total (amba)	Y				R	

Ambulatory Care: Dual Eligibles (ambb)	N				NR
Ambulatory Care: Disabled (ambc)	N				NR
Ambulatory Care: Other (ambd)	N				NR
Inpatient Utilization--General Hospital/Acute Care:	Y				R
Inpatient Utilization--General Hospital/Acute Care: Dual Eligibles (ipub)	N				NR
Inpatient Utilization--General Hospital/Acute Care:	N				NR
Inpatient Utilization--General Hospital/Acute Care:	N				NR
Identification of Alcohol and Other Drug Services:	Y	Y			R
Identification of Alcohol and Other Drug Services: Dual Eligibles (iadb)	N	N			NR
Identification of Alcohol and Other Drug Services:	N	N			NR
Identification of Alcohol and Other Drug Services:	N	N			NR
Mental Health Utilization: Total (mpta)	Y	Y			R
Mental Health Utilization: Dual Eligibles (mptb)	N	N			NR
Mental Health Utilization: Disabled (mptc)	N	N			NR
Mental Health Utilization: Other (mptd)	N	N			NR
Antibiotic Utilization: Total (abxa)	Y	Y			R
Antibiotic Utilization: Dual Eligibles (abxb)	N	N			NR
Antibiotic Utilization: Disabled (abxc)	N	N			NR
Antibiotic Utilization: Other (abxd)	N	N			NR
Relative Resource Use					
Relative Resource Use for People With Diabetes (rdi)	Y				R
Relative Resource Use for People With Asthma (ras)	Y	Y			R
Relative Resource Use for People With Cardiovascular Conditions (rca)	Y				R
Relative Resource Use for People With Hypertension (rhy)	Y				R
Relative Resource Use for People With COPD (rco)	Y				R
Health Plan Descriptive Information					
Board Certification (bcr)	Y				R
Total Membership (tln)	Y				R
Enrollment by Product Line: Total (enpa)	Y				R
Enrollment by Product Line: Dual Eligibles (enpb)	N				NR
Enrollment by Product Line: Disabled (enpc)	N				NR
Enrollment by Product Line: Other (enpd)	N				NR
Enrollment by State (ebs)	Y				R
Race/Ethnicity Diversity of Membership (rdm)	Y				R
Language Diversity of Membership (ldm)	Y				R
Weeks of Pregnancy at Time of Enrollment (wop)	Y		N		R